Predict your next investment

HEALTHCARE | Alternative Medicine
better-global.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Better

Better offers medical cannabis products. The company uses organic growing methods and active medical and agricultural research to help promote cannabis for medical use.On April 5th, 2021, Better was acquired by Canndoc at a valuation of $35M.

Better Headquarter Location

Hataasiya 4

Tel Aviv,

Israel

03-6355101

Latest Better News

CareDx Acquires MedActionPlan To Directly Support Patients With Better Adherence

Nov 10, 2021

CareDx Acquires MedActionPlan To Directly Support Patients With Better Adherence MedActionPlan adds a robust medication adherence platform to the CareDx digital suite, currently used in more than 100 hospitals and health systems Author: SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired MedActionPlan®, a New Jersey-based provider of medication safety and adherence technology and patient education. MedActionPlan is a leader in patient medication management for transplant patients. This acquisition adds to CareDx's goal of connecting offerings for transplant patients, including: MedActionPlan PRO: a medication management and adherence platform to simplify post-transplant medication regimens. It is used by more than 100 healthcare systems, with the majority being also transplant centers, to simplify post-transplant medication regimens. MyMedSchedule® Plus: a companion mobile app that works with MedActionPlan PRO to provide patients with up-to-date medication schedules and medication reminders to reinforce adherence. Patient Connect & MedActionPlan Dashboard: a tool that allows the healthcare team to monitor a patient's progress and send medication schedule updates. "Medication adherence and education are cornerstones to good transplant outcomes, and fit seamlessly with our suite of patient solutions," said Reg Seeto, CEO at CareDx. "We look forward to building on MedActionPlan's expertise and strong foundation to deliver solutions that are integrated with transplant centers to work seamlessly for transplant patients." "We are thrilled to be joining CareDx and look forward to working side by side to help transplant patients with their medical journey," said Tim Peters, president and founder, MedActionPlan. "Together with CareDx, we can reach more patients and offer more meaningful digital solutions to improve patient adherence and health outcomes." About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, please visit:  www.CareDx.com . Forward Looking StatementsThis press release includes forward-looking statements, including statements regarding MedActionPlan® (MAP) and its products and opportunities, and the potential benefits and results that may be achieved through the acquisition of MedActionPlan® (MAP). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks that CareDx does not realize all of the proposed benefits in acquiring MedActionPlan® (MAP), risks relating to the integration of MedActionPlan® (MAP) and general economic and market factors, among others discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by CareDx with the SEC on February 24, 2021 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. ContactsSasha KingChief Marketing Officer(415) 287-2393 sking@CareDx.com Investor RelationsIan Cooney(415) 722-4563 investor@CareDx.com

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Better

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Better in 3 CB Insights research briefs, most recently on Sep 28, 2021.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.